SteelPeak Wealth LLC grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 129.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,253 shares of the company’s stock after buying an additional 5,784 shares during the quarter. SteelPeak Wealth LLC’s holdings in CRISPR Therapeutics were worth $699,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the business. Foguth Wealth Management LLC. acquired a new position in shares of CRISPR Therapeutics in the 1st quarter valued at $1,008,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of CRISPR Therapeutics by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 16,876 shares of the company’s stock worth $1,150,000 after purchasing an additional 411 shares during the last quarter. Lincoln Capital Corp bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $204,000. Thrive Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $211,000. Finally, Wealthcare Advisory Partners LLC grew its holdings in shares of CRISPR Therapeutics by 7.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock worth $286,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.
CRISPR Therapeutics Trading Down 2.5 %
Shares of NASDAQ:CRSP traded down $1.37 during trading on Friday, hitting $54.01. 1,313,469 shares of the company’s stock were exchanged, compared to its average volume of 1,370,108. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10. The firm has a 50-day moving average price of $56.72 and a two-hundred day moving average price of $64.53. The firm has a market cap of $4.59 billion, a P/E ratio of -19.86 and a beta of 1.78.
Insider Buying and Selling
In related news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.
Analysts Set New Price Targets
Several research firms have recently weighed in on CRSP. Guggenheim reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday. Wells Fargo & Company lowered their target price on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Citigroup decreased their price objective on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd. Finally, Robert W. Baird raised their price objective on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $75.71.
View Our Latest Stock Report on CRSP
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
- Five stocks we like better than CRISPR Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- How to Invest in the Best Canadian Stocks
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Options Trading – Understanding Strike Price
- MarketBeat Week in Review – 6/24 – 6/28
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.